Answers are grounded in this paper and cite their sources.
The pace of discovery of new antiretroviral (ARV) drugs has slowed, although the efficacy and safety of once-daily fixed dose combinations have been extensively investigated. Several traditional ARV drugs remain in phase III clinical trials. This review summarizes current information on ARV drugs in phase III clinical trials and focuses on the development of ARV drugs in the next decade.
No takes yet. Share an insight, caveat, or question.
Xingquan Zhang (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: